Early use of erenumab in US real-world practice

Early use of erenumab in US real-world practice

Background: Erenumab, a monoclonal antibody (mAb) developed to block the calcitonin gene-related peptide (CGRP) receptor, is approved for the prevention of migraine in adults. This retrospective observational study sought to describe early real-world use of erenumab. Methods: This study used the Pra...

Full description

Bibliographic Details
Main Authors: Alina Bogdanov, Victoria Chia, Mark Bensink, Robert Urman, Lauren Fischer, Soeren Rasmussen, Christine Szekely, Lee Kallenbach
Format: Article
Language:English
Published: SAGE Publishing 2021-05-01
Series:Cephalalgia Reports
Online Access:https://doi.org/10.1177/25158163211020419

Similar Items

Similar Items